Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Biogen Inc.    BIIB

BIOGEN INC.

(BIIB)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsAnalyst Recommendations

Biogen : to Study Higher Dose of Spinraza in Spinal Muscular Atrophy

share with twitter share with LinkedIn share with facebook
share via e-mail
0
09/18/2019 | 08:08am EDT

By Colin Kellaher

Biogen Wednesday said it will launch a new study to evaluate whether a higher dose of Spinraza can provide greater efficacy in the treatment of the neuromuscular disease spinal muscular atrophy.

The Cambridge, Mass., biopharmaceutical company said it will conduct the phase 2/3 study at 50 sites around the world, with a projected enrollment of 126 patients of all ages.

Biogen said the trial will compare two loading doses of 50 milligrams 15 days apart followed by a maintenance dose of 28 milligrams every four months with the current FDA-approved program of four loading doses with 12-milligram maintenance doses every four months.

Spinal muscular atrophy is a rare genetic disease characterized by a loss of motor neurons in the spinal cord and lower brain stem, resulting in severe, progressive muscle atrophy and weakness.

Biogen licensed the global rights to develop, manufacture and commercialize Spinraza from Ionis Pharmaceuticals, which receives royalties on sales of the drug.

Write to Colin Kellaher at colin.kellaher@wsj.com

Stocks mentioned in the article
ChangeLast1st jan.
BIOGEN INC. -2.46% 220.06 Delayed Quote.-26.87%
IONIS PHARMACEUTICALS, INC. -1.33% 55.79 Delayed Quote.3.20%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on BIOGEN INC.
10/18GRAPHIC - TAKE FIVE : Super Saturday, Super Mario
RE
10/15Health-Care Stocks Get a Welcome Respite -- Update
DJ
10/15Health-Care Stocks Get a Welcome Respite
DJ
10/15Elizabeth Warren's Rise Is Battering Health-Care Stocks
DJ
10/15Elizabeth Warren's Rise Is Battering Health-Care Stocks
DJ
10/11SoftBank-backed Vir Biotechnology's shares tumble in market debut
RE
10/03BIOGEN INC. : - Landmark NURTURE Study of Infants with Spinal Muscular Atrophy T..
AQ
10/03BIOGEN : NURTURE study shows pre-symptomatic Spinal Muscular Atrophy (SMA) infan..
AQ
10/02Landmark NURTURE Study of Infants with Spinal Muscular Atrophy (SMA) Treated ..
GL
10/01BIOGEN : Names Sandrock Head of R&D As Ehlers Steps Down
DJ
More news
Financials (USD)
Sales 2019 14 141 M
EBIT 2019 7 441 M
Net income 2019 5 708 M
Finance 2019 141 M
Yield 2019 -
P/E ratio 2019 7,31x
P/E ratio 2020 7,38x
EV / Sales2019 2,86x
EV / Sales2020 2,66x
Capitalization 40 589 M
Chart BIOGEN INC.
Duration : Period :
Biogen Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BIOGEN INC.
Short TermMid-TermLong Term
TrendsBearishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 32
Average target price 254,96  $
Last Close Price 220,06  $
Spread / Highest target 60,4%
Spread / Average Target 15,9%
Spread / Lowest Target -9,12%
EPS Revisions
Managers
NameTitle
Michel Vounatsos Chief Executive Officer & Director
Stelios B. Papadopoulos Chairman
Jeffrey D. Capello Chief Financial Officer & Executive Vice President
Alfred W. Sandrock Chief Medical Officer & Executive Vice President
Mark Hernon Chief Information Officer & Senior Vice President
Sector and Competitors
1st jan.Capitalization (M$)
BIOGEN INC.-26.87%40 589
CSL LIMITED35.54%77 980
ALEXION PHARMACEUTICALS1.08%22 066
SAMSUNG BIOLOGICS CO LTD--.--%19 301
GRIFOLS19.13%18 295
WUXI BIOLOGICS CAYMAN INC--.--%13 163